Event-free survival in early polycythemia vera patients correlates with molecular response to ropeginterferon alfa-2b or hydroxyurea/best available therapy (PROUD-PV/CONTINUATION-PV).
作者信息
Kiladjian Jean-Jacques, Klade Christoph, Georgiev Pencho, Krochmalczyk Dorota, Gercheva-Kyuchukova Liana, Egyed Miklos, Dulicek Petr, Illes Arpad, Pylypenko Halyna, Sivcheva Lylia, Mayer Jiří, Yablokova Vera, Krejcy Kurt, Empson Victoria, Hasselbalch Hans C, Kralovics Robert, Gisslinger Heinz
机构信息
Université de Paris, AP-HP, Hôpital Saint-Louis Inserm, Centre d'Investigations Cliniques, INSERM Paris France.
AOP Orphan Pharmaceuticals GmbH Vienna Austria.
出版信息
Hemasphere. 2025 May 3;9(5):e70137. doi: 10.1002/hem3.70137. eCollection 2025 May.
Abstract
摘要
Zotero 插件